TFThomas E. Feasby

Thomas E. Feasby

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Thomas E. Feasby has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 13 March 2012
      • Vol. 6  (1) , e28-e34
    Open Access

    Appropriateness of the use of intravenous immune globulin before and after the introduction of a utilization control program

    by Thomas E Feasby, Hude Quan, Michelle Tubman, David Pi, Alan Tinmouth, Lawrence So, William A Ghali

    Intravenous immune globulin (IVIG) is an expensive and sometimes scarce blood product that carries some risk. It may often be used inappropriately. We evaluated the appropriateness of IVIG use before and after the introduction of an utilization control program to reduce inappropriate use. We used the RAND/UCLA Appropriateness Method to measure the appropriateness of IVIG use in the province of British Columbia (BC) in 2001 and 2003, before and after the introduction of a utilization control program designed to reduce inappropriate use. For comparison, we measured the appropriateness of use during the same periods in the province of Alberta, which had no control program. Of 2256 instances of IVIG use, 54.1% were deemed to be appropriate, 17.4% were of uncertain benefit, and 28.5% were deemed inappropriate. The frequency of inappropriate use in BC after the introduction of the utilization control program did not differ significantly from the frequency before the program or the frequency in Alberta. Almost half of IVIG use in BC and Alberta was judged to be inappropriate or of uncertain benefit, and the frequency of inappropriate use did not decrease after implementation of a utilization control program in BC. More effective utilization controls are necessary to prevent wasted resources and unnecessary risk to patients.


  • Open Access

    Real-World Replication of Randomized Controlled Trial Results for Carotid Endarterectomy

    by Thomas E. Feasby, James Kennedy, Hude Quan, Louis Girard, William A. Ghali

    Carotid endarterectomy (CE) is a widely performed operation for stroke prevention.1 Its efficacy has been demonstrated in several major international randomized controlled trials2-5 (RCTs), and its rate of use in the United States has increased in response to publication of these results.6,7 However, the risk reduction demonstrated in the clinical trials depends on low rates of perioperative stroke or death due to the procedure. This is especially true for CE performed in asymptomatic patients, for whom the absolute risk reduction demonstrated in the RCTs is small. For these patients, published guidelines have recommended that CE not be performed unless the stroke or death rate is less than 3%.8 Reluctance by some physicians to endorse asymptomatic carotid stenosis as an appropriate indication for CE has been largely based on the concern that this low level of perioperative mortality and morbidity is often not achieved in routine clinical practice.9,10 A meta-analysis of 46 case series of CE published between 1990 and 2000,11 inclusive, reported a death rate of 1.1% (95% confidence interval [CI], 0.9%-1.3%) for cases involving asymptomatic patients, compared with the death rate of 0.14% in the Asymptomatic Carotid Atherosclerosis Study (ACAS).4 When the combined end point of stroke or death was analyzed in the 8 studies with neurologist follow-up,11 the real-world rate was 4.30% (95% CI, 3.5%-5.2%) compared with 1.5% (95% CI, 0.6%-2.4%) in the ACAS.4 The recently completed Asymptomatic Carotid Stenosis Trial5 reported results similar to those of the ACAS, although it counted strokes in any arterial territory, did not exclude cardioembolic strokes, and has not demonstrated ipsilateral benefit. Furthermore, in the wake of the ACAS, it has not dispelled skepticism about whether these results can be replicated in clinical practice.12,13


  • Geographic Variation in the Rate of Carotid Endarterectomy in Canada

    by Thomas E. Feasby, Hude Quan, William A. Ghali

    Background and Purpose — Carotid endarterectomy (CEA) is an important method of stroke prevention, but its usage in Canada is not well known. The indications for CEA have been well informed by the recent clinical trials, but the impact of this information on the rate and regional variation in the rate of CEA is unknown. This study sought to determine the rate and the regional variation in the rate of CEA in Canada, its provinces, and census divisions for 1994–1997. Methods — Discharge data from all hospitals in Canada except Quebec were obtained from the Canadian Institute for Health Information for 1994–1997 and were searched for CEA by residential site. Rates and variations in rates were calculated. Results — The national age- and sex-adjusted rate per 100 000 people of CEA for those aged ≥40 years rose from 31.7 in 1994 to 40.5 in 1997. Provincial rates in 1997 varied from a low of 25.7 in Saskatchewan to high of 82.8 in Prince Edward Island. The census division rates varied even more, from a low of 0 in several divisions to a high of 179. Conclusions — The recent slight increase in CEA rates may reflect the release of new efficacy results for CEA, especially for asymptomatic carotid stenosis, but the rates are still far below US levels. The marked regional variation in rates may reflect differing views on the appropriateness of indications such as asymptomatic carotid stenosis for CEA and the inconsistency of published clinical practice guidelines.